Cuffe, Sinead
St. James's Hospital
4 papers on CoChat
Most cited papers
- Verified
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 10,089
- Verified
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 1,670
- Verified
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial
Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 182
- Verified
Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer
Malone, T., Schäfer, L., Simon, N., Heavey, S., Cuffe, S., Finn, S., Moore, G., & Gately, K. (2020) · Pharmacology & Therapeutics
PI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy
Cited by 33
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free